A phase 2 trial of SKB571 for injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities is a phase 2 interventional study registered as NCT07308106 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 70 participants planned, started 2026-04-03 and due to reach its primary completion in 2027-06-30. Interventions recorded: SKB571 for injection.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.